An interventional study of Amino Acid and chromium-picolinate containing drink and Placebo Drink in Type 2 Diabetes and Prediabetes, sponsored by Stoffwechselzentrum Rhein - Pfalz. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 636th largest by enrollment of the 688 interventional ones that give a count, is one of 28 that started in 2014, is one of 87 with no phase, and was the 455th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 25–69 · Healthy volunteers
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Ascletis Pharma (China) Co., Limited · Sites in Germany, United States, Czechia and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
756 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 104 · Phase 3 285 · Phase 4 79
First in 1998; this study’s year is marked. 28 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 218 across the 688 interventional studies, 1,552 across the 66 observational. Of the 655 that completed or were terminated, 263 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
597 of 756 have an industry lead sponsor. The 10 most frequent:
Stoffwechselzentrum Rhein - Pfalz is the lead sponsor of 3 studies on the registry; none are open to participants now.
Stoffwechselzentrum Rhein - Pfalz has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
18 of the studies in Diabetes Mellitus, Type 2 with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
Add all 18 to your calendar (.ics) → With an account.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It has previously been shown in healthy overweight subjects, that table water including a defined amount of amino acids and chromium can decrease the postprandial glucose and insulin response. In this study, the effect of this table water on glucose excursions after a test meal containing a defined amount of available carbohydrates, protein and fat will be studied in patients with early type 2 diabetes or prediabetes according to guidelines that are treated with dietary measures or metformin only. The study will be conducted in a cross -over design, double blinded and placebo controlled including 20 participants. The primary endpoint of the study is the incremental area under the curve for plasma glucose (iAUCgluc) within 180 minutes after ingestion of the meal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
Dietary Supplement: Amino Acid and chromium-picolinate containing drink · Dietary Supplement: Placebo Drink
Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
Dietary Supplement: Amino Acid and chromium-picolinate containing drink · Dietary Supplement: Placebo Drink
Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
Area under the curve for Glucose
Area under the curve for glucose will be measured within 180 minutes after a test meal. Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180').
Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal
AUC for insulin
Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180').
Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal
Markers of inflammation
Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180'). At these timepoints markers of inflammation will be measured (i.e. hsCRP and others)
Time frame: at 0', 15', 30', 60', 90', 120', 150', 180' post test meal
markers of lipid metabolism
Triglycerides, VLDL and other parameters of lipid metabolism are planned to be measured within 180 minutes after a test meal at 0', 15', 30', 60', 90', 120', 150', 180'.
Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal
Gut peptide hormones
Area under the curve for GLP-1, ghrelin, glucagone and GIP are measured within 180 minutes after the test meal.
Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal
The record gives a start of Aug 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stoffwechselzentrum Rhein - Pfalz